<?xml version='1.0' encoding='utf-8'?>
<document id="14709940"><sentence text="Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers."><entity charOffset="41-52" id="DDI-PubMed.14709940.s1.e0" text="venlafaxine" /><entity charOffset="54-64" id="DDI-PubMed.14709940.s1.e1" text="fluoxetine" /><entity charOffset="66-76" id="DDI-PubMed.14709940.s1.e2" text="sertraline" /><entity charOffset="82-92" id="DDI-PubMed.14709940.s1.e3" text="nefazodone" /><pair ddi="false" e1="DDI-PubMed.14709940.s1.e0" e2="DDI-PubMed.14709940.s1.e0" /><pair ddi="false" e1="DDI-PubMed.14709940.s1.e0" e2="DDI-PubMed.14709940.s1.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s1.e0" e2="DDI-PubMed.14709940.s1.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s1.e0" e2="DDI-PubMed.14709940.s1.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s1.e1" e2="DDI-PubMed.14709940.s1.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s1.e1" e2="DDI-PubMed.14709940.s1.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s1.e1" e2="DDI-PubMed.14709940.s1.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s1.e2" e2="DDI-PubMed.14709940.s1.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s1.e2" e2="DDI-PubMed.14709940.s1.e3" /></sentence><sentence text="An antidepressant for use in the patient receiving concomitant drug treatment, over-the-counter medications, or herbal products should lack cytochrome P-450 (CYP) 3A4 inductive or inhibitory activity to provide the least likelihood of a drug-drug interaction" /><sentence text=" This study addresses the potential of 4 diverse antidepressants (venlafaxine, nefazodone, sertraline, and fluoxetine) to inhibit or induce CYP3A4"><entity charOffset="66-77" id="DDI-PubMed.14709940.s3.e0" text="venlafaxine" /><entity charOffset="79-89" id="DDI-PubMed.14709940.s3.e1" text="nefazodone" /><entity charOffset="91-101" id="DDI-PubMed.14709940.s3.e2" text="sertraline" /><entity charOffset="107-117" id="DDI-PubMed.14709940.s3.e3" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.14709940.s3.e0" e2="DDI-PubMed.14709940.s3.e0" /><pair ddi="false" e1="DDI-PubMed.14709940.s3.e0" e2="DDI-PubMed.14709940.s3.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s3.e0" e2="DDI-PubMed.14709940.s3.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s3.e0" e2="DDI-PubMed.14709940.s3.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s3.e1" e2="DDI-PubMed.14709940.s3.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s3.e1" e2="DDI-PubMed.14709940.s3.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s3.e1" e2="DDI-PubMed.14709940.s3.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s3.e2" e2="DDI-PubMed.14709940.s3.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s3.e2" e2="DDI-PubMed.14709940.s3.e3" /></sentence><sentence text=" In a 4-way crossover design, 16 subjects received clinically relevant doses of venlafaxine, nefazodone, or sertraline for 8 days or fluoxetine for 11 days"><entity charOffset="80-91" id="DDI-PubMed.14709940.s4.e0" text="venlafaxine" /><entity charOffset="93-103" id="DDI-PubMed.14709940.s4.e1" text="nefazodone" /><entity charOffset="108-118" id="DDI-PubMed.14709940.s4.e2" text="sertraline" /><entity charOffset="133-143" id="DDI-PubMed.14709940.s4.e3" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.14709940.s4.e0" e2="DDI-PubMed.14709940.s4.e0" /><pair ddi="false" e1="DDI-PubMed.14709940.s4.e0" e2="DDI-PubMed.14709940.s4.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s4.e0" e2="DDI-PubMed.14709940.s4.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s4.e0" e2="DDI-PubMed.14709940.s4.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s4.e1" e2="DDI-PubMed.14709940.s4.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s4.e1" e2="DDI-PubMed.14709940.s4.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s4.e1" e2="DDI-PubMed.14709940.s4.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s4.e2" e2="DDI-PubMed.14709940.s4.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s4.e2" e2="DDI-PubMed.14709940.s4.e3" /></sentence><sentence text=" Treatments were separated by a 7- to 14-day washout period and fluoxetine was always the last antidepressant taken"><entity charOffset="64-74" id="DDI-PubMed.14709940.s5.e0" text="fluoxetine" /></sentence><sentence text=" CYP3A4 activity was evaluated for each subject at baseline and following each antidepressant using the erythromycin breath test (EBT) and by the pharmacokinetics of alprazolam (ALPZ) after 2-mg dose of oral ALPZ"><entity charOffset="104-116" id="DDI-PubMed.14709940.s6.e0" text="erythromycin" /><entity charOffset="166-176" id="DDI-PubMed.14709940.s6.e1" text="alprazolam" /><entity charOffset="178-182" id="DDI-PubMed.14709940.s6.e2" text="ALPZ" /><entity charOffset="208-211" id="DDI-PubMed.14709940.s6.e3" text="ALPZ" /><pair ddi="false" e1="DDI-PubMed.14709940.s6.e0" e2="DDI-PubMed.14709940.s6.e0" /><pair ddi="false" e1="DDI-PubMed.14709940.s6.e0" e2="DDI-PubMed.14709940.s6.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s6.e0" e2="DDI-PubMed.14709940.s6.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s6.e0" e2="DDI-PubMed.14709940.s6.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s6.e1" e2="DDI-PubMed.14709940.s6.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s6.e1" e2="DDI-PubMed.14709940.s6.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s6.e1" e2="DDI-PubMed.14709940.s6.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s6.e2" e2="DDI-PubMed.14709940.s6.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s6.e2" e2="DDI-PubMed.14709940.s6.e3" /></sentence><sentence text=" Compared to baseline, venlafaxine, sertraline, and fluoxetine caused no apparent inhibition or induction of erythromycin metabolism (P &gt; 0"><entity charOffset="23-34" id="DDI-PubMed.14709940.s7.e0" text="venlafaxine" /><entity charOffset="36-46" id="DDI-PubMed.14709940.s7.e1" text="sertraline" /><entity charOffset="52-62" id="DDI-PubMed.14709940.s7.e2" text="fluoxetine" /><entity charOffset="109-121" id="DDI-PubMed.14709940.s7.e3" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.14709940.s7.e0" e2="DDI-PubMed.14709940.s7.e0" /><pair ddi="false" e1="DDI-PubMed.14709940.s7.e0" e2="DDI-PubMed.14709940.s7.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s7.e0" e2="DDI-PubMed.14709940.s7.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s7.e0" e2="DDI-PubMed.14709940.s7.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s7.e1" e2="DDI-PubMed.14709940.s7.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s7.e1" e2="DDI-PubMed.14709940.s7.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s7.e1" e2="DDI-PubMed.14709940.s7.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s7.e2" e2="DDI-PubMed.14709940.s7.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s7.e2" e2="DDI-PubMed.14709940.s7.e3" /></sentence><sentence text="05)" /><sentence text=" For nefazodone, a statistically significant inhibition was observed (P &lt; 0"><entity charOffset="5-15" id="DDI-PubMed.14709940.s9.e0" text="nefazodone" /></sentence><sentence text="0005)" /><sentence text=" Nefazodone was also the only antidepressant that caused a significant change in ALPZ disposition, decreasing its area under the concentration-versus-time curve (AUC; P &lt; 0"><entity charOffset="1-11" id="DDI-PubMed.14709940.s11.e0" text="Nefazodone" /><entity charOffset="81-90" id="DDI-PubMed.14709940.s11.e1" text="ALPZ" /><pair ddi="false" e1="DDI-PubMed.14709940.s11.e0" e2="DDI-PubMed.14709940.s11.e0" /><pair ddi="false" e1="DDI-PubMed.14709940.s11.e0" e2="DDI-PubMed.14709940.s11.e1" /></sentence><sentence text="01), and increasing its elimination half-life (16" /><sentence text="4 vs" /><sentence text=" 12" /><sentence text="3 hours; P &lt; 0" /><sentence text="05) compared with values at baseline" /><sentence text=" No significant differences were found in the pharmacokinetics of ALPZ with any of the other antidepressants tested"><entity charOffset="66-69" id="DDI-PubMed.14709940.s17.e0" text="ALPZ" /></sentence><sentence text=" These results demonstrate in vivo that, unlike nefazodone, venlafaxine, sertraline, and fluoxetine do not possess significant metabolic inductive or inhibitory effects on CYP3A4"><entity charOffset="48-58" id="DDI-PubMed.14709940.s18.e0" text="nefazodone" /><entity charOffset="60-71" id="DDI-PubMed.14709940.s18.e1" text="venlafaxine" /><entity charOffset="73-83" id="DDI-PubMed.14709940.s18.e2" text="sertraline" /><entity charOffset="89-99" id="DDI-PubMed.14709940.s18.e3" text="fluoxetine" /><pair ddi="false" e1="DDI-PubMed.14709940.s18.e0" e2="DDI-PubMed.14709940.s18.e0" /><pair ddi="false" e1="DDI-PubMed.14709940.s18.e0" e2="DDI-PubMed.14709940.s18.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s18.e0" e2="DDI-PubMed.14709940.s18.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s18.e0" e2="DDI-PubMed.14709940.s18.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s18.e1" e2="DDI-PubMed.14709940.s18.e1" /><pair ddi="false" e1="DDI-PubMed.14709940.s18.e1" e2="DDI-PubMed.14709940.s18.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s18.e1" e2="DDI-PubMed.14709940.s18.e3" /><pair ddi="false" e1="DDI-PubMed.14709940.s18.e2" e2="DDI-PubMed.14709940.s18.e2" /><pair ddi="false" e1="DDI-PubMed.14709940.s18.e2" e2="DDI-PubMed.14709940.s18.e3" /></sentence><sentence text="" /></document>